Parsing the Split-Decision Victory for Biologics in COPD at HealthBulance.

Health care is our expertise. It's tough to keep up with the proliferation of monoclonal antibodies. Seems every day I'm confronted by a patient who's using a new drug with a name ending in "mab." That drug blocks a cellular receptor I haven't heard of that's involved in a cascade of interactions I

Medscape

Parsing the Split-Decision Victory for Biologics in COPD

Parsing the Split-Decision Victory for Biologics in COPD

It's tough to keep up with the proliferation of monoclonal antibodies. Seems every day I'm confronted by a patient who's using a new drug with a name ending in "mab." That drug blocks a cellular receptor I haven't heard of that's involved in a cascade of interactions I haven't thought about since medical school. The resulting disruption reduces disease burden, typically at great expense to the medical system, the patient, or both. We've truly entered the era of precision medicine. It's not enough to understand disease; you also must know its heterogeneous expression so that you can prescribe the 'mab that targets the biology responsible for variants in behavior.